Supplement



Figure S1. The ESI-MS spectrum (A) and ESI-MS/MS spectrum (B) of ophiopogonin B in negative ion mode.



Figure S2. The ESI-MS spectrum (A) and ESI-MS/MS spectrum (B) of Ophiogenin 3-O-α-L-rha-(1→2)-β-D-glc in negative ion mode.



Figure S3. The ESI-MS spectrum (A) and ESI-MS/MS spectrum (B) of (20R,25R)-26-O-β-D-glc-3β,26-dihydroxycholest-5-en-16,22-dioxo-3-O-α-L-rha(1→2)-β-D-Glc in negative ion mode.



Figure S4. The ESI-MS spectrum (A) and ESI-MS/MS spectrum (B) of Ophiofurspiside M in negative ion mode.



Figure S5. The ESI-MS spectrum (A) and ESI-MS/MS spectrum (B) of Xyl-Ophiofurspiside M in negative ion mode.



Figure S6. The ESI-MS spectrum (A) and ESI-MS/MS spectrum (B) of Ophiofurspiside A in negative ion mode.



Figure S7. The ESI-MS spectrum (A) and ESI-MS/MS spectrum (B) of Ophiopogonin H in negative ion mode.



Figure S8. The ESI-MS spectrum (A) and ESI-MS/MS spectrum (B) of SS10-SS14 in negative ion mode.



Figure S9. The ESI-MS spectrum (A) and ESI-MS/MS spectrum (B) of SS72-SS74 in negative ion mode.